Skip to Main Content

Never mind the conflicts, there are drugs to approve.

In a sorry turn of events, the Food and Drug Administration is facing a confidence-draining debacle thanks to its controversial approval of a pricey Alzheimer’s drug for which evidence appears suspect, at best.


Approval standards are being questioned and the acting FDA commissioner asked a federal watchdog to probe its dealings with Biogen, because the company quietly worked to curry favor with a top FDA official in charge of reviewing its drug.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment

There was an error saving your display name. Please check and try again.